Benzinga | Mar 23, 2021 07:03AM EDT

SVB Leerink Downgrades Alexion Pharmaceuticals to Market Perform, Lowers Price Target to $156

SVB Leerink analyst Geoffrey Porges downgrades Alexion Pharmaceuticals (NASDAQ:ALXN) from Outperform to Market Perform and lowers the price target from $196 to $156.